RRM2 showed significant risk in univariate analyses (HR = 1.291, 95% CI = 1.150-1.450, p-value = 0), and multivariate analyses (HR = 1.255, 95% CI = 1.112-1.415, p-value = 0), indicating it can predict tumor outcomes independently of the other six immune cells. Here, RRM2 is linked to neoplasm.